• About Us
    • Overview
    • Our Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Cell Manufacturing Advisory Board
    • Strategic Partners
  • Technology
    • Allogeneic Cell Therapy Platform
    • Oncolytic Virus Combinations
    • CD30 CAR-T Cell Therapy
    • Manufacturing
  • Pipeline
    • TT11X Allogeneic CD30 CAR EBVSTs
    • TT16 HER2 CAR Ts + CAdVEC
    • TT11 CD30 CAR Ts
    • TT11 CD30 CAR Ts + Nivolumab
    • Expanded Access
    • Scientific Publications
  • Investors & Media
    • Press Releases & Events
    • Interviews
  • Careers
  • Contact Us

What are you looking for?

Tessa Therapeutics – Cancer Immunotherapy Treatments
Tessa Therapeutics – Cancer Immunotherapy Treatments
Tessa Therapeutics – Cancer Immunotherapy Treatments
  • About Us
    • Overview
    • Our Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Cell Manufacturing Advisory Board
    • Strategic Partners
  • Technology
    • Allogeneic Cell Therapy Platform
    • Oncolytic Virus Combinations
    • CD30 CAR-T Cell Therapy
    • Manufacturing
  • Pipeline
    • TT11X Allogeneic CD30 CAR EBVSTs
    • TT16 HER2 CAR Ts + CAdVEC
    • TT11 CD30 CAR Ts
    • TT11 CD30 CAR Ts + Nivolumab
    • Expanded Access
    • Scientific Publications
  • Investors & Media
    • Press Releases & Events
    • Interviews
  • Careers
  • Contact Us
    Category Archives

    news-pressrelease

  • All
  • PR 2017
  • PR 2018
  • PR 2019
  • PR 2020
  • PR 2021
    • home-featured
    • news-pressrelease

    Tessa Therapeutics Enters into Cooperative Research and Development Agreement (CRADA) with the U.S. National Cancer Institute

    CRADA to support investigation of Tessa’s lead allogeneic cell therapy, TT11X, in several subtypes of…

    Continue Reading
    • home-featured
    • news-pressrelease

    Tessa Therapeutics Provides Strategic Outlook and Corporate Update for 2023

    Tessa Therapeutics announced today that the company will prioritize development of its allogeneic “off-the-shelf” CD30.CAR-modified…

    Continue Reading
    • home-featured
    • news-pressrelease

    Tessa Therapeutics Announces Updated Safety, Efficacy and Biomarker Data from Phase 2 Trial of Autologous CD30.CAR-T Therapy (TT11) in Relapsed or Refractory Classical Hodgkin Lymphoma

    Tessa Therapeutics today announced updated clinical data from the pilot stage of the ongoing Phase…

    Continue Reading
    • home-featured
    • news-pressrelease

    Tessa Therapeutics Announces New Clinical Data from Phase 1 Allogeneic Study Presented at 2022 Annual Meeting of American Society of Hematology (ASH)

    Tessa Therapeutics today announced enhanced clinical data from an ongoing Phase 1 study (NCT04288726) of…

    Continue Reading
    • home-featured
    • news-pressrelease

    Tessa Therapeutics, Baylor College of Medicine Execute Agreement For Global Commercial Rights to ‘Off-the-Shelf’ CAR-T Platform

    Tessa Therapeutics today announced the execution of an exclusive agreement with Baylor College of Medicine…

    Continue Reading
    • home-featured
    • news-pressrelease

    Tessa Therapeutics Announces Three Abstracts Highlighting Data from Autologous and Allogeneic Cell Therapy Programs Accepted for Presentation at 64th ASH Annual Meeting and Exposition

    Tessa Therapeutics today announced that three abstracts reporting data from clinical trials investigating the company’s…

    Continue Reading
    • home-featured
    • news-pressrelease

    Tessa Therapeutics to Present at the Stifel Healthcare Conference 2022

    Tessa Therapeutics today announced that Thomas Willemsen, President and CEO and Dr. Ivan D. Horak,…

    Continue Reading
    • home-featured
    • news-pressrelease

    Tessa Therapeutics to Participate in 2nd Annual Needham Biotech Private Company 1×1 Forum

    Tessa Therapeutics today announced that Thomas Willemsen, President and CEO, Wilson W. Cheung, Chief Financial…

    Continue Reading
    • home-featured
    • news-pressrelease

    Tessa Therapeutics Recognized in “Most Promising Off-the-Shelf Therapies” Category at Asia-Pacific Cell & Gene Therapy Excellence Awards 2022

    Tessa Therapeutics today announced that the company will host a scientific session during the SDCT-REMEDIS…

    Continue Reading
    • home-featured
    • news-pressrelease

    Tessa Therapeutics Appoints Thomas Willemsen as President and CEO

    Tessa Therapeutics today announced the appointment of Thomas Willemsen as its President and Chief Executive…

    Continue Reading
  • 1
  • 2
  • 3
  • 4
  • 5
  • →
  • ABOUT US
  • TECHNOLOGY
  • PIPELINE
  • PRESS RELEASES & EVENTS
  • CAREERS
  • CONTACT US

SITEMAP          PRIVACY POLICY

© 2021 Tessa Therapeutics Ltd. All rights reserved.